Subcutaneous versus intravenous bortezomib in two different induction therapies for fewly diagnosed multiple myeloma: Elektronische Ressourcedsubgroup analysis from the GMMG-MM5 trial - Merz, Maximilian; Bertsch, Uta; Mai, Elias K.; Hose, Dirk; Schurich, Bärbel; Goldschmidt, Hartmut (Blood, 2014)
Gesehen am 07.07.2015